Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.41 |
| ▸ | SELE | P16581 | 3/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040310 | 0.87 | EDNRA (0.45) | ALDH1A1HPGDHSD17B10ICAM1SELE | |
| SCHEMBL8443282 | 0.86 | ICAM1 (0.56) | ALDH1A1HPGDHSD17B10ICAM1SELE | |
| SCHEMBL5038317 | 0.83 | COMT (0.47) | ALDH1A1HPGDMAPK1HSD17B10ABCG2 | |
| SCHEMBL5035372 | 0.75 | IDO1 (0.34) | ALDH1A1ICAM1SELEVCAM1KDM4E | |
| SCHEMBL10372763 | 0.74 | MPO (0.44) | ALDH1A1ICAM1SELEVCAM1KDM4E | |
| SCHEMBL5034022 | 0.73 | ICAM1 (0.74) | ALDH1A1HPGDMAPK1HSD17B10ABCG2 | |
| SCHEMBL17502624 | 0.69 | CA12 (0.63) | ALDH1A1KMT2ACA12CA1CA2 | |
| SCHEMBL20562014 | 0.69 | KDM4E (0.46) | ALDH1A1HPGDMAPK1HSD17B10KDM4E | |
| SCHEMBL20561789 | 0.69 | KDM4E (0.60) | ALDH1A1HPGDHSD17B10KDM4ECYP1A2 | |
| SCHEMBL9568116 | 0.69 | KDM4E (0.46) | ALDH1A1HPGDMAPK1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| EP-1585745-A4 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | TRILLIUM THERAPEUTICS INC (CA) | 2008-07-09 | — | — | EP | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| EP-1585745-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | Arthron Limited (AU) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004058747-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | ARTHRON LIMITED (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 3832/4885HPGD 2422/4885MAPK1 3146/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 3832/4885HPGD 2422/4885MAPK1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.